BACKGROUND. Some adult patients presenting with unexplained pyrexia, serositis, skin rashes, arthralgia, myalgia, and other symptoms commonly found in autoinflammatory disorders may not fit a specific diagnosis, either because their clinical phenotype is nondiagnostic or genetic tests are negative. We used the term undifferentiated systemic autoinflammatory disorder (uSAID) to describe such cases. Given that well-defined autoinflammatory diseases show responses to IL-1 blockade, we evaluated whether anakinra was useful for both diagnosing and treating uSAID patients.
METHODS. We performed a retrospective analysis of consecutive patients presenting with uSAID between 2012–2015 who were treated with the recombinant IL-1 receptor antagonist anakinra. uSAID was diagnosed after excluding malignancy, infection, and pathogenic mutations in known hereditary fever syndromes (HFS) genes and where clinical criteria for adult onset Still’s disease (AOSD) were not met.
RESULTS. A total of 11 patients presented with uSAID (5 males and 6 females), with a mean time to diagnosis of 3.5 years (1–8 years). Patients were unresponsive or only partially controlled on disease-modifying antirheumatic drug (DMARD)/steroid treatment. Anakinra controlled symptoms within 4–6 weeks of starting treatment in 9 of 11 cases. Two patients discontinued therapy — one due to incomplete response and another due to severe injection-site reactions.
CONCLUSION. This retrospective case series demonstrates that the spectrum of poorly defined autoinflammatory disorders that show responsiveness to anakinra is considerable. Anakinra seems a viable treatment option for these patients, who are unresponsive to standard steroid/DMARD treatments. Moreover, given the mechanisms of action, response to anakinra implicates underlying IL-1 dysregulation in the disease pathogenesis of responding uSAIDs patients.
Stephanie R. Harrison, Dennis McGonagle, Sharmin Nizam, Stephen Jarrett, Jeroen van der Hilst, Michael F. McDermott, Sinisa Savic
Title and authors | Publication | Year |
---|---|---|
Case Report: Efficacy, safety, and favorable long-term outcome of early treatment with IL-1 inhibitors in a patient with chronic infantile neurological cutaneous articular (CINCA) syndrome caused by NLRP3 mosaicism
Costagliola G, D\u2019Elios S, Cappelli S, Massei F, Maestrini G, Beni A, Peroni D, Consolini R |
Frontiers in Pediatrics | 2024 |
Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment
Birnboim-Perach R, Benhar I |
International journal of biological sciences | 2024 |
Systematic genetic analysis of pediatric patients with autoinflammatory diseases
Poker Y, von Hardenberg S, Hofmann W, Tang M, Baumann U, Schwerk N, Wetzke M, Lindenthal V, Auber B, Schlegelberger B, Ott H, von Bismarck P, Viemann D, Dressler F, Klemann C, Bergmann AK |
Frontiers in Genetics | 2023 |
Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study.
Alexeeva E, Shingarova M, Dvoryakovskaya T, Lomakina O, Fetisova A, Isaeva K, Chomakhidze A, Chibisova K, Krekhova E, Kozodaeva A, Savostyanov K, Pushkov A, Zhanin I, Demyanov D, Suspitsin E, Belozerov K, Kostik M |
Frontiers in Medicine | 2023 |
Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe?
Š Fingerhutová, E Jančová, P Doležalová |
Frontiers in Pediatrics | 2022 |
Therapeutic effect of NLRP3 inhibition on hearing loss induced by systemic inflammation in a CAPS-associated mouse model
Ma JH, Lee E, Yoon SH, Min H, Oh JH, Hwang I, Sung Y, Ryu JH, Bok J, Yu JW |
EBioMedicine | 2022 |
Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases.
Della Casa F, Vitale A, Lopalco G, Ruscitti P, Ciccia F, Emmi G, Cattalini M, Wiesik-Szewczyk E, Maggio MC, Ogunjimi B, Sfikakis PP, Tufan A, Al-Mayouf SM, Del Giudice E, Aragona E, La Torre F, Sota J, Colella S, Di Cola I, Iacono D, Mattioli I, Jahnz-Rózyk K, Joos R, Laskari K, Gaggiano C, Abbruzzese A, Cipriani P, Rozza G, AlSaleem A, Yildirim D, Tarsia M, Ragab G, Ricci F, Cardinale F, Korzeniowska M, Frassi M, Caggiano V, Saad MA, Pereira RM, Berlengiero V, Gentileschi S, Guerriero S, Giani T, Gelardi V, Iannone F, Giardini HAM, Almaghlouth IA, Kardas RC, Ait-Idir D, Frediani B, Balistreri A, Fabiani C, Rigante D, Cantarini L |
Frontiers in Medicine | 2022 |
Biologic Therapy for Refractory Immune Checkpoint Inhibitor Colitis
Alorfi NM, Alourfi MM |
Biologics : targets & therapy | 2022 |
Improving Diagnosis and Clinical Management of Acquired Systemic Autoinflammatory Diseases
Al-Hakim A, Mistry A, Savic S |
Journal of inflammation research | 2022 |
Syndrome of Undifferentiated Recurrent Fever (SURF): An Emerging Group of Autoinflammatory Recurrent Fevers
R Papa, F Penco, S Volpi, D Sutera, R Caorsi, M Gattorno |
Journal of Clinical Medicine | 2021 |
USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Still’s Disease in Elderly Patients
M Delplanque, A Aouba, P Hirsch, P Fenaux, J Graveleau, F Malard, D Roos-Weil, N Belfeki, L Drevon, A Oganesyan, M Groh, M Mahévas, J Razanamahery, G Maigne, M Décamp, S Miranda, T Quemeneur, J Rossignol, L Sailler, M Sébert, L Terriou, A Sevoyan, Y Hakobyan, S Georgin-Lavialle, A Mekinian |
Journal of Clinical Medicine | 2021 |
NLRP3 Inflammasome-Mediated Inflammation in Acute Pancreatitis
A Ferrero-Andrés, A Panisello-Roselló, J Roselló-Catafau, E Folch-Puy |
International journal of molecular sciences | 2020 |
Mixed results with baricitinib in biological-resistant adult-onset Still’s disease and undifferentiated systemic autoinflammatory disease
M Kacar, J Fitton, AK Gough, MH Buch, DG McGonagle, S Savic |
RMD Open | 2020 |
The off-label use of anakinra in pediatric systemic autoinflammatory diseases
V Maniscalco, S Abu-Rumeileh, MV Mastrolia, E Marrani, I Maccora, I Pagnini, G Simonini |
Therapeutic Advances in Musculoskeletal Diseases | 2020 |
Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis
MH Buch, S Eyre, D McGonagle |
Nature Reviews Rheumatology | 2020 |
Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review
A TUFAN, HJ LACHMANN |
2020 | |
Efficacy and safety of anakinra for undifferentiated autoinflammatory diseases in children: a retrospective case review
S Garg, K Wynne, E Omoyinmi, D Eleftheriou, P Brogan |
2019 | |
Palindromic rheumatism as part of the rheumatoid arthritis continuum
K Mankia, P Emery |
Nature Reviews Rheumatology | 2019 |
Follow the complex bread crumbs: A review of autoinflammation for the general paediatrician
P Tsoukas, RM Laxer |
Paediatrics & child health | 2019 |
The classification, genetic diagnosis and modelling of monogenic autoinflammatory disorders
F Moghaddas, SL Masters |
Clinical Science | 2018 |
Anakinra Therapy for Non-cancer Inflammatory Diseases
G Cavalli, CA Dinarello |
Frontiers in pharmacology | 2018 |
Treatment of Inflammatory Diseases with IL-1 Blockade
CA Dinarello |
Current Otorhinolaryngology Reports | 2018 |
Long-term prognosis, treatment, and outcome of patients with fever of unknown origin in whom no diagnosis was made despite extensive investigation: A questionnaire based study
CM Mulders-Manders, C Engwerda, A Simon, JW van der Meer, CP Bleeker-Rovers |
Medicine | 2018 |
Overview of the IL-1 family in innate inflammation and acquired immunity
CA Dinarello |
Immunological Reviews | 2017 |
The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges
G Lazaros, K Antonatou, D Vassilopoulos |
Frontiers in Medicine | 2017 |
Lessons from characterization and treatment of the autoinflammatory syndromes:
I Aksentijevich, MF McDermott |
Current Opinion in Rheumatology | 2017 |